Equities analysts forecast that Seres Therapeutics Inc (NASDAQ:MCRB) will report earnings of ($0.69) per share for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Seres Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.76) and the highest estimate coming in at ($0.62). Seres Therapeutics also posted earnings per share of ($0.69) during the same quarter last year. The company is expected to issue its next earnings results on Thursday, August 2nd.
On average, analysts expect that Seres Therapeutics will report full year earnings of ($2.53) per share for the current fiscal year, with EPS estimates ranging from ($2.71) to ($2.31). For the next year, analysts anticipate that the business will report earnings of ($2.76) per share, with EPS estimates ranging from ($3.47) to ($2.18). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Seres Therapeutics.
Seres Therapeutics (NASDAQ:MCRB) last announced its earnings results on Wednesday, May 9th. The biotechnology company reported ($0.69) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.75) by $0.06. The company had revenue of $3.97 million during the quarter, compared to the consensus estimate of $3.00 million. Seres Therapeutics had a negative net margin of 277.79% and a negative return on equity of 150.44%.
Shares of MCRB stock traded up $0.47 on Friday, hitting $9.51. The stock had a trading volume of 597,401 shares, compared to its average volume of 177,517. The company has a current ratio of 3.60, a quick ratio of 3.60 and a debt-to-equity ratio of 0.85. Seres Therapeutics has a 12-month low of $6.65 and a 12-month high of $17.42.
In related news, insider John G. Aunins sold 14,279 shares of the firm’s stock in a transaction dated Friday, June 15th. The shares were sold at an average price of $8.57, for a total transaction of $122,371.03. Following the completion of the sale, the insider now owns 170,206 shares in the company, valued at $1,458,665.42. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Roger Pomerantz sold 40,057 shares of the firm’s stock in a transaction dated Friday, June 22nd. The stock was sold at an average price of $9.36, for a total transaction of $374,933.52. Following the sale, the chief executive officer now owns 297,812 shares of the company’s stock, valued at approximately $2,787,520.32. The disclosure for this sale can be found here. Insiders have sold 95,340 shares of company stock valued at $854,807 in the last 90 days. 37.10% of the stock is currently owned by corporate insiders.
A number of large investors have recently modified their holdings of MCRB. Wells Fargo & Company MN boosted its position in Seres Therapeutics by 107.2% during the fourth quarter. Wells Fargo & Company MN now owns 29,183 shares of the biotechnology company’s stock worth $296,000 after purchasing an additional 15,097 shares during the period. Virtus Fund Advisers LLC bought a new position in Seres Therapeutics during the fourth quarter worth about $358,000. Arrowstreet Capital Limited Partnership bought a new position in Seres Therapeutics during the fourth quarter worth about $143,000. Citadel Advisors LLC bought a new position in Seres Therapeutics during the fourth quarter worth about $1,396,000. Finally, Spark Investment Management LLC bought a new position in Seres Therapeutics during the fourth quarter worth about $514,000. Hedge funds and other institutional investors own 79.53% of the company’s stock.
Seres Therapeutics Company Profile
Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which is in Phase III clinical study to treat multiply recurrent Clostridium difficile infection (CDI).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.